First-trimester screening for trisomy 21 with adjustment for biochemical results of previous pregnancies

Fetal Diagnosis and Therapy

Volumn 30, Issue 3, 2011, Pages 194-202

  Wright, David ^a   Syngelaki, Argyro ^b,c   Birdir, Cahit ^b   Bedei, Ivonne ^b   Nicolaides, Kypros H ^b,c  

^a UNIVERSITY OF PLYMOUTH   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

First trimester screening; Free hCG; Nuchal translucency; PAPP A; Trisomy 21

Indexed keywords

PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; FIRST TRIMESTER PREGNANCY; GENETIC SCREENING; GESTATION PERIOD; HUMAN; MATERNAL AGE; PRIORITY JOURNAL; TRISOMY 21;

ADULT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; HUMANS; LIKELIHOOD FUNCTIONS; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 80855148202     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000328710     Document Type: Article

References (14)

1. Nicolaides KH: Screening for fetal aneuploi-dies at 11 to 13 weeks. Prenat Diagn 2011; 31: 7-15.
2. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH: First-trimester screening for trisomy 21 by free beta-human chorionic go-nadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008; 31: 493-502.
3. Spencer K: Between pregnancy biological variability of first trimester markers of Down syndrome and the implications for screening in subsequent pregnancies: an issue revisited. Prenat Diagn 2002; 22: 874-876. (Pubitemid 35175985)
4. Robinson HP, Fleming JE: A critical evaluation of sonar crown rump length measurements. Br J Obstet Gynaecol 1975; 182: 702-710.
5. Snijders RJ, Noble P, Sebire NJ, Souka AP, Nicolaides KH: UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352: 343-346. (Pubitemid 28352196)
6. Syngelaki A, Chelemen T, Dagklis T, Allan L, Nicolaides KH: Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks. Prenat Diagn 2011; 31: 90-102.
7. Snijders RJ, Sebire NJ, Nicolaides KH: Maternal age and gestational age-specific risk for chromosomal defects. Fetal Diagn Ther 1995; 10: 356-367.
8. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH: A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008; 31: 376-383.
9. Office for National Statistics: Birth Statistics: Review of the Registrar General on Births and Patterns of Family Building in England and Wales. Series FM1, Nos 29-31, Stationary Office, London, 2002.
10. Holding S, Cuckle H: Maternal serum screening for Down's syndrome taking account of the results of a previous pregnancy. Prenat Diagn 1994; 14: 321-322.
11. Dar H, Merksamer R, Berdichevsky D, David M: Maternal serum marker levels in consecutive pregnancies: a possible genetic predisposition to abnormal levels. Am J Med Genet 1996; 61: 154-157.
12. Spencer K: Between-pregnancy biological variability of maternal serum alpha fetopro-tein and free beta hCG: implications for Down syndrome screening in subsequent pregnancies. Prenat Diagn 1997; 17: 39-45. (Pubitemid 27046250)
13. Nicolaides KH: Turning the pyramid of prenatal care. Fetal Diagn Ther 2011; 29: 183-196.
14. Anderson TW: An Introduction to Multivar-iate Statistical Analysis, 3rd ed. New York, Wiley, 2002.